Back to top

Image: Bigstock

Azul's (AZUL) October Traffic Increases 41% Month on Month

Read MoreHide Full Article

With gradual increase in air-travel demand, Azul S.A. (AZUL - Free Report) reported impressive October traffic numbers on the back of month-over-month double-digit rise in total traffic (domestic and international). However, consolidated load factor (% of seats filled by passengers) falls month over month consolidated traffic increase was less than the capacity expansion.

Consolidated load factor fell 0.9 percentage points month over month to 79.3%. In the international front, load factor declined 9.3 percentage point from September levels to 65.3%. In the domestic front, the metric didn’t show any movement (traffic increase was equal to capacity expansion).

Consolidated traffic (measured in revenue passenger kilometers or RPKs) surged 41% on a month-over-month basis. Both international traffic and domestic traffic soared 38% and 41.3%, respectively. Consolidated capacity (measured in available seat kilometers/ASKs) jumped 42.6% owing to 41.3% domestic expansion and 57.5% international expansion from the September reading.

 Zacks Rank & Stocks to Consider

Azul currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the Zacks Transportation sector are Knight-Swift Transportation Holdings Inc. (KNX - Free Report) , Canadian Pacific Railway Limited (CP - Free Report) and Werner Enterprises, Inc. (WERN - Free Report) . Knight-Swift sports a Zacks Rank #1(Strong Buy), while Canadian Pacific and Werner carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Long-term expected earnings per share (three to five years) growth rate for Knight-Swift, Canadian Pacific and Werner is pegged at 15%, 8.5% and 13%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>
 

Published in